Shao-Chun Chang

3.1k total citations · 3 hit papers
7 papers, 2.2k citations indexed

About

Shao-Chun Chang is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Shao-Chun Chang has authored 7 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 3 papers in Cell Biology and 2 papers in Oncology. Recurrent topics in Shao-Chun Chang's work include Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Cellular transport and secretion (2 papers) and Lipid metabolism and biosynthesis (2 papers). Shao-Chun Chang is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Cellular transport and secretion (2 papers) and Lipid metabolism and biosynthesis (2 papers). Shao-Chun Chang collaborates with scholars based in United States, Japan and South Korea. Shao-Chun Chang's co-authors include William Dowhan, Philip Heacock, Eugenia Mileykovskaya, Dennis R. Voelker, Do‐Youn Oh, Yin Yang, Weijing Sun, Daniel J. Renouf, Pilar García‐Alfonso and Allen Lee Cohn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Lancet Oncology.

In The Last Decade

Shao-Chun Chang

7 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

2015 652 citations Josep Tabernero, Takayuki Yoshino et al. The Lancet Oncology profile →
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 634 citations Andrew X. Zhu, Joon Oh Park et al. The Lancet Oncology profile →
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

2019 480 citations Eileen M. O’Reilly, Do‐Youn Oh et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shao-Chun Chang United States	7	1.2k	676	637	448	349	7	2.2k
Sara Toffanin United States	14	515 0.4×	890 1.3×	1.2k 1.9×	266 0.6×	793 2.3×	18	2.3k
Zhaoshi Zeng United States	27	1.3k 1.1×	415 0.6×	1.0k 1.6×	397 0.9×	897 2.6×	37	2.6k
Zhong‐Zhe Lin Taiwan	22	740 0.6×	498 0.7×	418 0.7×	552 1.2×	332 1.0×	65	1.5k
Binkui Li China	30	743 0.6×	932 1.4×	1.3k 2.0×	471 1.1×	950 2.7×	103	2.8k
Po‐Lin Lai Taiwan	20	548 0.5×	495 0.7×	933 1.5×	205 0.5×	485 1.4×	25	1.7k
Frauke Bentzien United States	10	665 0.6×	372 0.6×	821 1.3×	522 1.2×	298 0.9×	12	2.1k
Ying‐Hao Shen China	23	413 0.4×	499 0.7×	571 0.9×	247 0.6×	418 1.2×	75	1.5k
Sandrine Boyault France	14	351 0.3×	503 0.7×	1.0k 1.6×	260 0.6×	503 1.4×	20	1.7k
Stefania Brozzetti Italy	21	468 0.4×	337 0.5×	586 0.9×	307 0.7×	393 1.1×	50	1.6k
Tiziana Pressiani Italy	19	735 0.6×	634 0.9×	353 0.6×	440 1.0×	348 1.0×	76	1.5k

Countries citing papers authored by Shao-Chun Chang

Since Specialization

Citations

This map shows the geographic impact of Shao-Chun Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shao-Chun Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shao-Chun Chang more than expected).

Fields of papers citing papers by Shao-Chun Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shao-Chun Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shao-Chun Chang. The network helps show where Shao-Chun Chang may publish in the future.

Co-authorship network of co-authors of Shao-Chun Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Shao-Chun Chang. A scholar is included among the top collaborators of Shao-Chun Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shao-Chun Chang. Shao-Chun Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

O’Reilly, Eileen M., Do‐Youn Oh, Neesha C. Dhani, et al.. (2019). Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Oncology. 5(10). 1431–1431. 480 indexed citations breakdown →

Zhu, Andrew X., Joon Oh Park, Baek‐Yeol Ryoo, et al.. (2015). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 16(7). 859–870. 634 indexed citations breakdown →

Tabernero, Josep, Takayuki Yoshino, Allen Lee Cohn, et al.. (2015). Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. The Lancet Oncology. 16(5). 499–508. 652 indexed citations breakdown →

Zou, Jun, Shao-Chun Chang, Jasna Marjanovic, & Philip W. Majerus. (2008). MTMR9 Increases MTMR6 Enzyme Activity, Stability, and Role in Apoptosis. Journal of Biological Chemistry. 284(4). 2064–2071. 46 indexed citations

Ungewickell, Alexander, Christopher Hugge, Marina V. Kisseleva, et al.. (2005). The identification and characterization of two phosphatidylinositol-4,5-bisphosphate 4-phosphatases. Proceedings of the National Academy of Sciences. 102(52). 18854–18859. 96 indexed citations

Kawasaki, Kiyoshi, Osamu Kuge, Shao-Chun Chang, et al.. (1999). Isolation of a Chinese Hamster Ovary (CHO) cDNA Encoding Phosphatidylglycerophosphate (PGP) Synthase, Expression of Which Corrects the Mitochondrial Abnormalities of a PGP Synthase-defective Mutant of CHO-K1 Cells. Journal of Biological Chemistry. 274(3). 1828–1834. 80 indexed citations

Chang, Shao-Chun, Philip Heacock, Eugenia Mileykovskaya, Dennis R. Voelker, & William Dowhan. (1998). Isolation and Characterization of the Gene (CLS1 ) Encoding Cardiolipin Synthase in Saccharomyces cerevisiae. Journal of Biological Chemistry. 273(24). 14933–14941. 175 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact